Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Advancements in drug development
3.2.1.2 Improved diagnostic techniques
3.2.1.3 Growing disease awareness initiatives
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of treatment
3.2.2.2 Competition from alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021–2032 ($ Mn)
5.1 Key trends
5.2 Hypomethylating drugs
5.3 Immune therapy drugs
5.3.1 Immunomodulatory drugs
5.3.2 Immunosuppressive drugs
5.4 Anti-anemics drugs
5.5 Thrombopoietin receptor agonists
Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021–2032 ($ Mn)
6.1 Key trends
6.2 Oral
6.3 Parenteral
Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021–2032 ($ Mn)
7.1 Key trends
7.2 Refractory anemia with excess blasts (RAEB)
7.3 Refractory cytopenia with multilineage dysplasia (RCMD)
7.4 Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)
7.5 Other cancer types
Chapter 8 Market Estimates and Forecast, By Medication, 2021–2032 ($ Mn)
8.1 Key trends
8.2 Branded
8.3 Generic
Chapter 9 Market Estimates and Forecast, By Age Group, 2021–2032 ($ Mn)
9.1 Key trends
9.2 Above 80
9.3 70-79
9.4 60-69
9.5 50-59
9.6 40-49
9.7 Below 40
Chapter 10 Market Estimates and Forecast, By End-user, 2021–2032 ($ Mn)
10.1 Key trends
10.2 Healthcare providers
10.2.1 Hospitals
10.2.2 Specialty clinics
10.3 Patients
10.4 Other end-users
Chapter 11 Market Estimates and Forecast, By Region, 2021–2032 ($ Mn)
11.1 Key trends
11.2 North America
11.2.1 U.S.
11.2.2 Canada
11.3 Europe
11.3.1 Germany
11.3.2 UK
11.3.3 France
11.3.4 Spain
11.3.5 Italy
11.3.6 Netherland
11.3.7 Rest of Europe
11.4 Asia Pacific
11.4.1 Japan
11.4.2 China
11.4.3 India
11.4.4 Australia
11.4.5 South Korea
11.4.6 Rest of Asia Pacific
11.5 Latin America
11.5.1 Brazil
11.5.2 Mexico
11.5.3 Argentina
11.5.4 Rest of Latin America
11.6 Middle East and Africa
11.6.1 Saudi Arabia
11.6.2 South Africa
11.6.3 UAE
11.6.4 Rest of Middle East and Africa
Chapter 12 Company Profiles
12.1 Amgen Inc.
12.2 Astex Pharmaceuticals, Inc.
12.3 Bristol-Myers Squibb Company (Celgene Corporation)
12.4 Cipla Limited
12.5 Dr. Reddy's Laboratories Inc.
12.6 Hikma Pharmaceuticals PLC
12.7 Johnson & Johnson Services, Inc.
12.8 Lupin Limited
12.9 Otsuka America Pharmaceutical, Inc.
12.10 Pfizer, Inc.
12.11 Sandoz
12.12 Shilpa Medicare Limited
12.13 Sun Pharmaceutical Industries, Inc.
12.14 Takeda Pharmaceutical Company Limited
12.15 Teva Pharmaceutical Industries Ltd
